Reaction

Lower Respiratory Tract Congestion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,681 reports · 60 co-occurring drugs

As of the last recalculation, Lower Respiratory Tract Congestion appears in 1,681 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is OMALIZUMAB (PRR 41.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Omalizumab	244	41.3	41.4
Ciclesonide	43	40.1	40.2
Diphenhydramine Hydrochloride Capsule, Liquid Filled	51	30.4	30.5
Desoximetasone	37	24.6	24.6
Fluticasone Propionate And Salmeterol Xinafoate	105	23.0	23.1
Umeclidinium	14	19.5	19.5
Tocilizumab	156	18.6	18.6
Fluticasone Furoate And Vilanterol Trifenatate	52	18.4	18.5
Cortisone Acetate	18	18.2	18.3
Umeclidinium Bromide And Vilanterol Trifenatate	23	17.3	17.3
Budesonide And Formoterol Fumarate Dihydrate	123	16.8	16.9
Tranexamic Acid	12	16.8	16.8
Risedronate Sodium	40	16.3	16.3
Rabeprazole	26	14.7	14.8
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	23	14.0	14.0
Naproxen Sodium, Pseudoephedrine Hydrochloride	23	14.0	14.0
Methylprednisolone Sodium Succinate	51	14.0	14.0
Hydrocortisone Sodium Succinate	10	13.2	13.3
Albuterol Sulfate	270	13.2	13.2
Ocrelizumab	60	12.4	12.4
Fluticasone Furoate	12	12.3	12.4
Montelukast Sodium	113	12.2	12.3
Selexipag	24	11.7	11.7
Tiotropium Bromide	117	11.3	11.3
Diphenhydramine Hydrochloride	139	11.2	11.2
Elexacaftor, Tezacaftor, And Ivacaftor	11	11.0	11.0
Diltiazem Hydrochloride Extended-Release Tablets	10	10.9	10.9
Erythromycin	16	10.7	10.7
Cetirizine Hydrochloride Allergy	25	10.4	10.4
Cetirizine Hydrochloride Tablets	25	10.4	10.4
Fluticasone Propionate And Salmeterol	33	10.0	10.0
Ambrisentan	95	9.9	9.9
Pirfenidone	32	9.9	9.9
Amikacin	13	9.5	9.5
Guaifenesin	23	9.5	9.5
0Xygen	36	9.2	9.2
Oxygen	36	9.2	9.2
Naproxen Sodium Tablet, Coated	10	9.2	9.2
Naproxen Sodium, Coated Tablets	10	9.2	9.2
Naproxen Sodium 220Mg	10	9.2	9.2
Mepolizumab	35	8.9	8.9
Epoprostenol	9	8.6	8.6
Ivacaftor	5	7.8	7.8
Oseltamivir Phosphate	15	7.7	7.7
Golimumab	49	7.3	7.3
Mometasone Furoate And Formoterol Fumarate Dihydrate	9	7.2	7.2
Riociguat	18	6.9	6.9
Tofacitinib Citrate	7	6.6	6.6
Oxycodone And Acetaminophen	12	6.4	6.4
Dornase Alfa	10	6.3	6.3
Ofatumumab	16	6.0	6.0
Treprostinil	53	5.4	5.4
Tobramycin	10	5.2	5.2
Nintedanib	12	4.8	4.8
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	4.7	4.8
Canagliflozin	11	4.6	4.6
Benralizumab	7	4.3	4.3
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	14	4.2	4.2
Ledipasvir And Sofosbuvir	5	3.2	3.2
Palivizumab	3	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.